EpiVario

EpiVario is a private, preclinical-stage biotech pioneering a novel neuroepigenetic platform targeting the enzyme ACSS2 to disrupt maladaptive memories underlying addiction and PTSD. Spun out of the University of Pennsylvania's Epigenetics Institute, the company leverages foundational discoveries by its scientific founders to develop small molecule inhibitors. Recent milestones include key patent issuances, NIH grant funding, and strategic portfolio licensing, positioning it to address significant unmet needs in neuropsychiatry.

Neuroepigenetic platform targeting the enzyme ACSS2 (Acetyl-CoA Synthetase 2) to modulate histone acetylation and gene expression required for the consolidation and reconsolidation of long-term memories, particularly maladaptive memories underlying addiction and PTSD.

EpiVario operates in the emerging field of neuroepigenetics and memory modulation. Direct competitors are likely few but may include other biotechs or academic groups targeting epigenetic regulators of memory (e.g., HDAC inhibitors). It also competes broadly with developers of pharmacotherapies for addiction and PTSD, though its mechanism is distinct from current standard-of-care.